Agilent Technologies Completes Acquisition of ProZyme

Agilent Technologies, Inc. (NYSE:A) today announced that it has
completed the acquisition of ProZyme, Inc., a leading provider of glycan
reagents, kits and standards. This acquisition expands Agilent’s
portfolio of biopharma consumables.

Founded in 1990, Hayward-Calif. based ProZyme is an industry leading
developer and manufacturer of glycan reagents, kits and standards, which
are required for efficient sample prep in the analysis of free glycans.
Glycobiology is one of the fastest-growing segments in biopharma, as
glycans play diverse roles in biotherapeutics, novel drug development,
the study of bacterial physiology, and proteomics research.

The acquisition of ProZyme follows the recent acquisition of Ultra
Scientific, a leading provider of chemical standards and certified
reference materials.

“These acquisitions both support Agilent’s long-term strategy to provide
customers with more workflow-specific consumables and solutions to help
them achieve economic, operational and scientific success,” said Padraig
McDonnell, vice president and general manager of Agilent’s Chemistries
and Supplies Division.

“We are excited to be adding the ProZyme team and technology to our
capabilities,” he continued. “Together we can accelerate the development
of the solutions our customers need to advance their biopharma research.”

Financial terms of the deal are not being disclosed.

More information on ProZyme products and solutions is available at

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences,
diagnostics, and applied chemical markets. With more than 50 years of
insight and innovation, Agilent instruments, software, services,
solutions, and people provide trusted answers to its customers’ most
challenging questions. The company generated revenues of $4.47 billion
in fiscal 2017 and employs 14,200 people worldwide. Information about
Agilent is available at

Forward-Looking Statements

This news release contains forward-looking statements as defined in the
Securities Exchange Act of 1934 and is subject to the safe harbors
created therein. The forward-looking statements contained herein
include, but are not limited to, statements regarding the capabilities
and expertise the acquisition brings, the ability to supply industry
requirements and acceleration of growth. These forward-looking
statements involve risks and uncertainties that could cause Agilent’s
results to differ materially from management’s current expectations.
Such risks and uncertainties include, but are not limited to, the
ability to integrate ProZyme’s operations with Agilent’s, retain key
employees, meet customer expectations and realize efficiencies from the
combined businesses. In addition, other risks that Agilent faces in
running its operations include the ability to execute successfully
through business cycles; the ability to meet and achieve the benefits of
its cost-reduction goals and otherwise successfully adapt its cost
structures to continuing changes in business conditions; ongoing
competitive, pricing and gross-margin pressures; the risk that our
cost-cutting initiatives will impair our ability to develop products and
remain competitive and to operate effectively; the impact of
geopolitical uncertainties and global economic conditions on our
operations, our markets and our ability to conduct business; the ability
to improve asset performance to adapt to changes in demand; the ability
of our supply chain to adapt to changes in demand; the ability to
successfully introduce new products at the right time, price and mix;
the ability of Agilent to successfully integrate recent acquisitions;
the ability of Agilent to successfully comply with certain complex
regulations; and other risks detailed in Agilent’s filings with the
Securities and Exchange Commission, including our quarterly report on
Form 10-Q for the quarter ended April 30, 2018. Forward-looking
statements are based on the beliefs and assumptions of Agilent’s
management and on currently available information. Agilent undertakes no
responsibility to publicly update or revise any forward-looking

NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available on the Agilent news site at

View source version on

Leave a Comment

Your email address will not be published. Required fields are marked *